Eduardo Bruno Martins
Directeur Technique/Scientifique/R&D chez SAGIMET BIOSCIENCES INC.
Fortune : 306 329 $ au 30/06/2024
Profil
Eduardo Bruno Martins founded Martins Bruno Consulting LLC.
Dr. Martins also currently works at Sagimet Biosciences, Inc., as Chief Medical Officer from 2021.
Dr. Martins also formerly worked at SciClone Pharmaceuticals LLC, as Vice President-Medical Affairs & Medical Director from 1997 to 2005, Allergan, Inc., as Vice President-Clinical Development from 2018 to 2020, InterMune, Inc., as Vice President-Medical Affairs, Dynavax Technologies Corp., as Vice President-Clinical Development, Eiger BioPharmaceuticals, Inc., as SVP-Liver & Infectious Diseases Drug Development, AbbVie, Inc., as Vice President-Clinical Development, and Federal University of Rio de Janeiro, as Professor from 1995 to 1999.
Dr. Martins received his doctorate degree in 1995 from the University of Oxford and doctorate degree in 1986 from Federal University of Rio de Janeiro.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 17/11/2023 | 89 570 ( 0,29% ) | 306 329 $ | 30/06/2024 |
Postes actifs de Eduardo Bruno Martins
| Sociétés | Poste | Début |
|---|---|---|
| SAGIMET BIOSCIENCES INC. | Directeur Technique/Scientifique/R&D | 01/02/2021 |
Anciens postes connus de Eduardo Bruno Martins
| Sociétés | Poste | Fin |
|---|---|---|
| ALLERGAN, INC. | Corporate Officer/Principal | 01/05/2020 |
| SCICLONE PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2005 |
| Federal University of Rio de Janeiro | Corporate Officer/Principal | 01/01/1999 |
| ABBVIE INC. | Corporate Officer/Principal | - |
| Martins Bruno Consulting LLC | Fondateur | - |
Formation de Eduardo Bruno Martins
| University of Oxford | Doctorate Degree |
| Federal University of Rio de Janeiro | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| ABBVIE INC. | Health Technology |
| SAGIMET BIOSCIENCES INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Allergan, Inc.
 Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
SciClone Pharmaceuticals LLC
 SciClone Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology SciClone Pharmaceuticals LLC was engaged in the development of therapeutic treatment for oncology, infectious diseases, and cardiovascular disorders. It was also offering ZADAXIN for the treatment of hepatitis B, hepatitis C, certain cancers, and used as immune system enhancer, and DC Bead which is used for the novel treatment of liver cancer. The company was founded in 1990 and was headquartered in San Mateo, CA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Eiger BioPharmaceuticals, Inc. /Old/
 Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Health Technology |
| Martins Bruno Consulting LLC |
